Recent Findings on Epigenetic Gene Abnormalities Involved in Uterine Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2017 Nov 29

PMID 29181164

Authors

Megumi Yanokura

Kouji Banno

Yusuke Kobayashi

Hiroyuki Nomura

Shigenori Hayashi

Eiichiro Tominaga

Daisuke Aoki

Affiliations

Soon will be listed here.

Abstract

Selective aberrant genetic effects that do not depend on abnormal DNA sequences are referred to as epigenetic abnormalities and are involved in carcinogenesis. In uterine cancer, various genes involved in apoptosis, cell cycle, DNA repair, cell proliferation and cell adhesion are abnormally methylated, resulting in gene silencing. Reversal of such epigenetic abnormalities in cancer cells is a potential strategy for cancer therapy, and studies on epigenetic abnormalities and treatment methods in uterine cancer are in progress. These include the evaluation of 5-hydroxymethylcytosine, which is present in cancer tissues at lower levels compared with those in normal tissues, as a prognostic marker in cervical cancer; combination therapy with 5-azacytidine and cisplatin; combination treatment focusing on tumor necrosis factor-related apoptosis-inducing ligand in cervical cancer; studies focusing on DNA mismatch repair in endometrial cancer; and use of a demethylating agent to reactivate tumor suppressor genes and inhibit tumor proliferation. Detection of epigenetic changes using biomarkers may be used for histological classification, evaluation of disease progression and identification of compounds that are able to modulate epigenetic changes and may be useful for uterine cancer treatment.

References

Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A . Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep. 2006; 16(6):1189-96. View

Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H . Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). Oncol Rep. 2009; 22(5):967-72. DOI: 10.3892/or_00000523. View

Chmelarova M, Kos S, Dvorakova E, Spacek J, Laco J, Ruszova E . Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium. Clin Chem Lab Med. 2014; 52(8):1229-34. DOI: 10.1515/cclm-2013-0162. View

Aoki K, Taketo M . Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007; 120(Pt 19):3327-35. DOI: 10.1242/jcs.03485. View

Narayan G, Arias-Pulido H, Nandula S, Basso K, Sugirtharaj D, Vargas H . Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res. 2004; 64(9):2994-7. DOI: 10.1158/0008-5472.can-04-0245. View

Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B . Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. Genes Chromosomes Cancer. 2015; 55(2):177-89. DOI: 10.1002/gcc.22325. View

Boers A, Wang R, van Leeuwen R, Klip H, de Bock G, Hollema H . Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 2016; 8:29. PMC: 4784352. DOI: 10.1186/s13148-016-0196-3. View

Lee K . Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers. J Cancer Prev. 2014; 18(4):351-4. PMC: 4189440. DOI: 10.15430/jcp.2013.18.4.351. View

Jascur T, Boland C . Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 2006; 119(9):2030-5. DOI: 10.1002/ijc.22023. View

10.

Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D . Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66(15):7810-7. DOI: 10.1158/0008-5472.CAN-06-1114. View

11.

Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C . Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol. 2009; 30(3):267-70. View

12.

Sanchez-Vega F, Gotea V, Petrykowska H, Margolin G, Krivak T, DeLoia J . Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. Epigenetics. 2013; 8(12):1355-72. PMC: 3933495. DOI: 10.4161/epi.26701. View

13.

Bischoff J, Ignatov A, Semczuk A, Schwarzenau C, Ignatov T, Krebs T . hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 2012; 29(8):889-900. DOI: 10.1007/s10585-012-9478-0. View

14.

Iyer L, Tahiliani M, Rao A, Aravind L . Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle. 2009; 8(11):1698-710. PMC: 2995806. DOI: 10.4161/cc.8.11.8580. View

15.

Roz L, Gramegna M, Ishii H, Croce C, Sozzi G . Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci U S A. 2002; 99(6):3615-20. PMC: 122572. DOI: 10.1073/pnas.062030799. View

16.

Sasaki M, Oh B, Dharia A, Fujimoto S, Dahiya R . Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer. Mol Carcinog. 2000; 29(2):59-66. DOI: 10.1002/1098-2744(200010)29:2<59::aid-mc2>3.0.co;2-6. View

17.

Kang S, Lee J, Jeon E, Lee S, Kim H, Kim H . RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer. 2006; 119(6):1316-21. DOI: 10.1002/ijc.21991. View

18.

Yi T, Li J, Han X, Guo J, Qu Q, Guo L . DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy. 2012; 58(1):19-29. DOI: 10.1159/000333077. View

19.

Moreno-Bueno G, Fernandez-Marcos P, Collado M, Tendero M, Rodriguez-Pinilla S, Garcia-Cao I . Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 2007; 67(5):1927-34. DOI: 10.1158/0008-5472.CAN-06-2687. View

20.

Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A, Schneider-Stock R . p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol. 2003; 129(10):589-96. DOI: 10.1007/s00432-003-0482-2. View